Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ELA026
- Development stage
- Phase 3
- Lead developer
- Electra Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous (iv), Subcutaneous (sc)
01
Overview
ELA026 is a first-in-class monoclonal antibody that targets signal regulatory proteins (SIRP) on the cell surface of myeloid cells and T lymphocytes. It is developed by Electra Therapeutics for the treatment of secondary hemophagocytic lymphohistiocytosis (sHLH), a rare and life-threatening hyperinflammatory condition. ELA026 works by depleting pathogenic immune cells responsible for the cytokine storm associated with sHLH.
- Other names
- ELA-026ELA026ELA 026
02
Targets
SIRPA (Signal-regulatory protein alpha)SIRPG (Signal-regulatory protein gamma)SIRPB1 (Signal-regulatory protein beta-1)
Beyond the preview
Go deeper on ELA026.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ELA026.